Literature DB >> 16834737

Preliminary results of HBV DNA testing of Polish haemophilia patients--lack of occult HBV infection.

J Windyga1, E Brojer, A Gronowska, P Grabarczyk, K Mikulska, A B Szczepanik, E Stefańska, A Buczma.   

Abstract

Identification of hepatitis B virus (HBV) infection in the absence of surface antigen (HbsAg) became possible with the introduction of HBV DNA detection methods. Such occult HBV infection was diagnosed recently in about half of the Japanese HBsAg-negative haemophilia patients. The aim of our study was to assess the prevalence of occult HBV infection in Polish severe haemophilia population on the sample of 115 haemophilia A and B patients (mean age 34.9 +/- 10.9) treated with non-virus inactivated clotting factor preparations before 1995. HBV DNA was detected in nine HBsAg-positive patients (7.8%). The mean HBV DNA load was 72,800 IU mL(-1) (250-400,000 IU mL(-1)). Hepatitis C virus (HCV) RNA was found in six out of nine HBV-positive patients. In conclusion, HBV DNA was identified only in HBsAg-positive patients. Unlike in Japan, the frequency of occult HBV infection in Polish haemophilia population seems extremely rare or absent.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16834737     DOI: 10.1111/j.1365-2516.2006.01293.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  3 in total

1.  Epidemiology of occult hepatitis B infection among thalassemic, hemophilia, and hemodialysis patients.

Authors:  Mohammad Kazemi Arababadi; Behzad Nasiri Ahmadabadi; Hassan Yousefi Daredor; Derek Kennedy
Journal:  Hepat Mon       Date:  2012-05-30       Impact factor: 0.660

2.  Occult Hepatitis B Virus Infection among β-Thalassemia Major Patients in Ahvaz City, Iran.

Authors:  Fatemeh Amirhashchi; Azarakhsh Azaran; Seyed Saeid Seyedian; Shahram Jalilian; Bijan Keikhaei
Journal:  Am J Trop Med Hyg       Date:  2021-10-04       Impact factor: 3.707

3.  Epidemiological Profile of Hemophilia in Baghdad-Iraq.

Authors:  Kamal Abdul Razzaq Kadhim; Faris Hasan Al-Lami; Kadhim Hussein Baldawi
Journal:  Inquiry       Date:  2019 Jan-Dec       Impact factor: 1.730

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.